On this page
A frozen-berry virus report answers a defined analytical question about the material tested. A valid “not detected” result means the named target was not detected under the stated method and conditions. It does not establish that every berry in the shipment is free of that target. A positive molecular result identifies viral genetic material; it does not, by itself, measure infectious capability.
For an importer or QA reviewer, the useful task is to connect that result to the sample, method, controls and prevention records. Those connections determine how much the report can contribute to a documented decision. Start with the complete report and its limitations, then ask the laboratory and responsible food-safety team to resolve the points that affect your order.
Start with the target and the tested material
“Virus testing” is too broad a description for a purchasing requirement. Name the targets requested and check that the report addresses them individually. Hepatitis A virus and human norovirus are different targets; norovirus testing may distinguish genogroups GI and GII. A result for one target does not fill an empty result field for another, even when all appear on the same laboratory quotation.
Frozen whole strawberries in a blue liner. Connect the named product form to the sample code and lot on the report.
The BSI public overview of BS EN ISO 15216-2:2019 covers detection of hepatitis A virus and norovirus GI and GII in specified materials, including soft fruit. It also states that the method has not been validated for all food types, including multicomponent foods. The published scope is a starting point for questions; it is not evidence that a particular laboratory has verified every berry product you buy.
Describe the material precisely: whole strawberries, raspberry pieces, a berry puree or a blend containing other ingredients. Include any treatment or formulation information relevant to the laboratory’s assessment. A quotation originally prepared for whole berries may need review when the product becomes a sweetened preparation. Ask the laboratory to confirm the applicable matrix scope and how any departure is reported.
Method identity matters as much as its familiar acronym. RT-qPCR uses reverse transcription and real-time polymerase chain reaction to detect a specified RNA target through a molecular signal. A report should identify the method and version used, including a laboratory modification where relevant. Do not assume that two reports carrying the words “PCR tested” used identical extraction, detection or interpretation procedures.
Also distinguish a qualitative detection report from a quantitative result. If the report gives detected or not detected, do not create a numerical concentration from it. If it reports genome copies, check the stated units, calculation basis and quantification limitations. Neither a target name nor the presence of a decimal number tells you what material that number represents.
Before reviewing conformity, connect the laboratory sample code to the supplier lot and the actual shipment. A complete report for an unidentified sample can be analytically useful yet commercially incomplete. Ask who collected the material, when it was collected, which packaging was sampled and whether the submitted material came from the lot now being offered. Keep the chain of identification with the report.
Read a negative result within its sampling limits
The quantity received by the laboratory and the portion actually analysed are different fields. A courier may deliver several bags, while the method uses a defined portion from the submitted material. Request both pieces of information. The delivery weight should not be copied into a certificate summary as the analysed weight unless that is what the laboratory actually tested.
Conceptual sampling boundaries. The pictured carton count and portion size are illustrative, not a prescribed sampling plan or a claim of complete lot coverage.
Sampling also has a coverage question: where did the submitted material come from? Several increments from one accessible carton are not equivalent to a plan that selects packages across a defined lot. The appropriate plan depends on the purpose, lot structure, method and applicable requirements. There is no universal carton count in this guide that can turn every negative result into an all-lot assurance.
The FDA’s FY 2019–2023 frozen-berry assignment report explains its use of multiple subsamples because hazards may be distributed unevenly. Its collection scheme was designed for that assignment and changed during the work. It provides a useful example of why collection details belong with an interpretation, rather than a ready-made sampling rule for every commercial order.
Consider a fictional comparison. Report A says that the requested target was not detected in a valid test of identified portions collected under the agreed plan. Report B uses the same result wording, but the sender cannot identify which cartons supplied the sample. The laboratory result in B is not automatically false. Its connection to the shipment is weaker, and that missing connection needs to be resolved before the team treats the reports as equivalent evidence.
Discuss compositing before collection. Combining material from several packages changes the relationship between the original units and the laboratory test. The laboratory should confirm that the proposed pooling approach fits its validated method and explain what the reported result represents. Do not create a large combined sample simply because it appears to cover more cartons, or assume a single composite preserves the same ability to detect low-level contamination as separate analyses.
Ask what the method’s detection limit means for the specified matrix and reporting basis. A limit expressed per reaction is not automatically the same as a limit per gram of original berries. A low stated detection limit also does not eliminate collection uncertainty. Keep analytical sensitivity and sampling coverage as two separate questions in the review.
A second negative result can add information when it follows a justified plan. It cannot retrospectively make an unidentified first sample representative. Retain the original report, the reason for additional work and the relationship between the samples so that the final decision reflects the evidence actually obtained.
Check whether the analytical controls support the result
A blank target result is not enough to establish a valid negative. The laboratory must determine whether its extraction and detection process performed acceptably. Ask for a clear validity statement and any qualifications that affect interpretation. You usually need the meaning of the controls and the laboratory’s conclusion, rather than every raw instrument file.
Illustrative control questions: recovery through the process, interference with detection and unintended contamination. The symbols show no actual control result or laboratory procedure.
FDA BAM Chapter 26 distinguishes extraction controls from internal amplification controls. The former help assess whether the extraction process worked; the latter help identify interference with the amplification response. Its explanation also cautions that the extraction control is not a determination of assay sensitivity. These are different checks, so a statement that “the machine ran correctly” does not answer all of them.
Recovery information concerns how effectively a control material was carried through the relevant analytical process. It does not describe the percentage of cartons sampled or prove that every target particle in the berries was recovered. Where the report gives a recovery value, ask which control it refers to, which stages it covers and whether it met the acceptance rule for that method and sample.
Inhibition concerns interference that can reduce the expected molecular response. Its presence can matter particularly when interpreting an apparent absence of the target. Ask whether the laboratory assessed inhibition and whether any corrective analytical work affected the reported detection capability. A qualified or invalid result should remain visibly qualified in your procurement summary.
Controls also address contamination introduced during the analysis. A negative control and a positive control have different purposes. The 2023 laboratory accreditation case study by D’Agostino illustrates how process controls, amplification checks and control contamination affect reporting. Its laboratory-specific examples are not universal numerical acceptance criteria. Use the current method and the performing laboratory’s documented interpretation.
Keep recovery, inhibition and target detection separate when discussing an unusual report. The presence of a valid target signal can require a different interpretation from an absent signal accompanied by failed controls. It is not sound to invent a rule that every control problem erases a positive finding, or that every instrument run without a target signal may be called negative. Refer the actual combination to the laboratory.
If testing cannot produce a valid conclusion from the submitted material, ask what the laboratory can report and what additional work is needed. Clarify whether it proposes further work on retained extract, another portion of the submitted sample or a newly collected sample. Those options answer different questions. Record which was used and keep any change in sample coverage visible.
The same case study notes that partial detections can occur in low-level competency samples. That reinforces the need to understand a method’s performance claim rather than treating a quoted detection limit as a promise of detection in every individual low-level test. It does not supply a reason to disregard an actual positive result from your shipment.
Separate an RNA signal from an infectivity conclusion
A molecular result and a measurement of infectious capability are different kinds of evidence. Detecting the requested RNA sequence supports the analytical finding under the method. It does not directly tell the reviewer how many infectious particles are present or what probability of illness follows from eating a serving of that product.
Conceptual symbols distinguish RNA detection from infectious capability. This is not microscopy, an actual virus image or an infectivity result.
The FDA frozen-berry report explicitly acknowledges that the methods used in its assignment did not distinguish presence from infectivity. It also describes adding analysis of a second genome region and sequence characterisation. Additional molecular confirmation can strengthen target identification, but confirmation of a sequence should not be relabelled as an infectivity test.
Food Standards Scotland’s 2023 oyster assessment explains the same PCR distinction for norovirus. That source concerns oysters: its serving assumptions and risk categories should not be transferred to berries. The relevant point here is the difference between the analytical signal and the separate question of infectious capability.
That limitation works in both directions. A positive RNA result does not establish a measured infectious dose. It also does not establish that the detected material is harmless or that the lot may be released. The responsible team must assess the result with the applicable requirements, incident information and product use. “PCR cannot prove infectivity” is not a substitute for that assessment.
Read terms such as presumptive, confirmed, detected below a quantification limit and inconclusive exactly as the laboratory defines them. Ask what additional analytical work, if any, is pending. Avoid shortening all of these descriptions to “positive” or “negative” in a shared spreadsheet when the omitted qualification could change the next action.
Similarly, do not compare raw cycle values from different laboratories as though they were a direct ranking of shipment risk. First establish whether the methods, calibration, extraction and reporting conventions support the proposed comparison. Where a quantitative interpretation is needed, request the laboratory’s supported result and limitations rather than making a conversion from an isolated instrument value.
The result should trigger a clear question for the people responsible for the food-safety decision. It may concern confirmation, sample identity, the wider lot, an incident investigation or the suitability of the intended use. Keep that question explicit so that a discussion about analytical uncertainty does not obscure the need for a documented response.
Connect testing to the prevention programme
A test examines submitted material after collection. Preventive controls address how contamination can be avoided through the supply chain. Both can contribute information, but a certificate cannot describe all the practices used before the sample was taken. Review the records relevant to the actual source and handling stages rather than assuming that testing makes those records unnecessary.
Frozen raspberries retain their recognisable drupelet form. Review the source and handling records relevant to the actual order.
FDA’s berry prevention strategy addresses hygiene, worker health, sanitary facilities, water and cross-contamination risks. It also identifies areas where further knowledge is needed. For a buyer, those topics provide a basis for focused supplier questions; the strategy does not certify the practices of any particular grower, processor or shipment.
The American Frozen Food Institute’s berry-virus information points to industry guidance spanning growing, harvesting, packing and freezing. Guidance availability and a supplier’s implementation are separate facts. Ask what programme applies to the proposed supply chain and what evidence is available, without treating an industry resource as a mandatory global rule or a supplier approval.
Make requests specific enough to receive useful information. For example, ask which operation handles harvest hygiene, how relevant water information is reviewed and how concerns are escalated between the grower, packing operation and freezing facility. The answer should identify responsibility and the records available for review. A general statement that staff receive training may leave the main question unanswered.
Check the connection to the material being purchased. If a supplier provides a procedure or audit record, identify its holder, site, scope and applicable period. Determine whether it covers the relevant activity and source. A good document from another operation does not resolve an information gap for this order merely because the company names are related.
Include the intended use in the discussion. A product entering a separately assessed processing step presents a different review context from one intended for use without such a step. The laboratory report does not establish the suitability of a finished-product process. Give the responsible food-safety team the actual application and supplier information, including any treatment claims requiring supporting evidence.
Keep test history in context as well. A series of valid results can support a review of performance over time, but record changes in source, matrix, method and sampling plan. Otherwise, the trend may combine unlike evidence. Investigate a new concern on its merits instead of treating a history of negative reports as permission to ignore it.
Agree the laboratory questions before a release decision
Set the reporting requirements before the sample is collected. That gives the laboratory a chance to identify a scope problem and lets the buyer agree how the result will be used. The following authored table is a report-review aid. It contains no regulatory limit, required sampling count or automatic release criterion.
| Question | Information to request | What it resolves |
|---|---|---|
| What was tested? | Berry form, sample code, lot linkage and named viral targets | Whether the report addresses the material and target requested |
| How was it collected? | Collector, date, packages or increments, submitted and analysed quantities | The relationship between shipment, sample and analytical portion |
| Which method applies? | Method version, matrix scope, modifications and reporting basis | Whether the method fits the proposed product and comparison |
| Was the result valid? | Recovery, inhibition and other relevant control conclusions | Whether a reported absence or signal has analytical qualifications |
| What does the wording mean? | Detection or quantification limit, units and confirmation status | Which inference the result actually supports |
| Who decides the next action? | Agreed criteria, responsible reviewer and any hold or investigation record | How evidence becomes an accountable disposition decision |
Ask the laboratory to state any result that falls outside its accredited scope and explain its relevant competence or verification. An accreditation logo alone does not identify which test, matrix and method are covered. Review the current scope with the laboratory where accreditation is part of your requirement; do not rely on an old service brochure.
Agree the communication route for qualified, invalid or detected results. Identify who receives them, who contacts the laboratory and who controls the related inventory decision. Where the order uses a hold pending review, keep the hold linked to the actual lot. Receipt of an email should not silently change the stock status before the responsible reviewer has reached a conclusion.
If further sampling or testing is proposed after a concern, document its purpose first. State which uncertainty it is intended to resolve and how all results will be considered together. Selecting a later negative report and discarding an earlier finding creates an incomplete record. Preserve the chronology and seek the appropriate technical and regulatory direction for the case.
The final record should identify the evidence reviewed, any unresolved limitations, the responsible decision maker and the resulting action. It should also distinguish laboratory interpretation from commercial acceptance. That allows another colleague to understand why the lot was held, investigated, accepted under the applicable process or otherwise dispositioned, without treating the certificate as a guarantee it never offered.
Coordinate the information for your berry order
We supply frozen berries through long-term partner factories and coordinate the inspection scope and available supporting information for agreed orders. Our quality-control and inspection coordination helps connect the request to the selected product and partner.
Send the berry and form, intended use, destination and volume, together with the named targets and laboratory requirements. We will review the request, confirm what information is available and identify points requiring further clarification with the partner factory or your laboratory.
References
- BSI: BS EN ISO 15216-2:2019 public scope overview.
- FDA: FY 2019–2023 frozen-berry sampling assignment report.
- FDA: BAM Chapter 26, July 2022 edition.
- D’Agostino: laboratory accreditation case study, 2023.
- Food Standards Scotland: oyster risk-assessment summary, 2023.
- FDA: prevention strategy for enteric viruses in berries.
- AFFI: enteric viruses in berries and industry guidance.
